Navigation Links
Christopher Brennan Joins PharmaNet Development Group as General Counsel
Date:9/22/2009

PRINCETON, N.J., Sept. 22 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Christopher S. Brennan has joined the Company as general counsel.

"We are very pleased to have Chris join the PharmaNet Development Group management team," commented Jeffrey P. McMullen, president and chief executive officer. "His diversified experience and expertise will bring valuable insight to the Company and support our growth strategies."

Previously, Mr. Brennan held the position of general counsel at a specialty pharmaceutical company and worked in private practice as a corporate transactional attorney at two prominent, multi-national law firms -- Cravath, Swaine & Moore LLP and Dechert LLP. While at these two global law firms, Mr. Brennan worked along side management teams from various Fortune 500 companies while helping them to successfully undertake and complete company "mission critical" transactions in the areas of mergers and acquisitions, corporate financing, joint ventures, licensing, corporate partnering, private financing and public securities -- all primarily in the pharmaceutical and emerging life science market place.

Mr. Brennan graduated from Fordham University School of Law with honors. For the five years prior to entering law school, he managed multi-million dollar, high-technology projects and led large project teams from various disciplines as a Captain in the United States Air Force.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
2. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
3. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
4. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
7. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
8. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
9. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
10. DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice
11. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob ... in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. ... They bonded over an interest in the potential of stem cell therapy and a fast ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North ... to isolate single cells and provide visual documentation of monoclonality for use in ...
(Date:9/18/2017)... --  Montrium , a growing leader in Electronic Trial Master ... groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic Studies (MAPS). ... MAPS Public Benefit ... ... to MDMA for the treatment of Posttraumatic Stress Disorder (PTSD). MAPS ...
(Date:9/14/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... company, will gather the most innovative minds in pharma and biotech at the ... is a two-day collaborative conference that brings together the world’s most progressive clinical ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):